Burcon NutraScience Corp.

  • WKN: 157793
  • ISIN: CA1208311029
  • Land: Kanada

Nachricht vom 26.08.2019 | 18:24

Burcon Receives Notice of Allowance from the United States Patent Office for Peazazz Pea Protein Patent

DGAP-News: Burcon NutraScience Corp. / Key word(s): Miscellaneous

26.08.2019 / 18:24
The issuer is solely responsible for the content of this announcement.


Burcon Receives Notice of Allowance from the United States Patent Office for Peazazz Pea Protein Patent

Vancouver, British Columbia, August 21, 2019 - Burcon NutraScience Corporation (TSX: BU), a global technology leader in the development of plant-based proteins, announced today that it has received a notice of allowance from the United States Patent and Trademark Office for a patent application covering certain valuable attributes of Burcon's Peazazz(R) pea protein. A notice of allowance from the United States Patent and Trademark Office is a written notification that a patent application has cleared internal review and is pending issuance and will grant in the near future.

"We are pleased to announce this important Peazazz pea protein patent allowance, which will add to our sizable patent portfolio," said Johann F. Tergesen, Burcon's president and chief executive officer, adding, "Burcon has made a huge financial investment researching and developing our plant-based protein technologies. Protecting that investment through a deliberate and calculated patent strategy is core to our long-term business plan."

U.S. patent application 13/556,357, which covers certain valuable properties of Peazazz including its exceptional solubility and clarity in solution at low pH, was allowed on August 7, 2019. This patent allowance adds to Burcon's existing patent portfolio of 268 issued patents in various countries, including 67 issued U.S. patents, and in excess of 260 additional pending patent applications, 43 of which are U.S. patent applications. The patent allowance which is the subject of this news release will be issued as a granted U.S. patent in the near future.

Peazazz(R) pea protein

Peazazz(R) is a uniquely soluble, clean and neutral-tasting pea protein that is perfect for dairy alternative products. Through Burcon's proprietary extraction and purification processes, this pea protein tastes and functions unlike any other pea protein on the market. Peazazz(R) has clean flavour characteristics and excellent solubility that allow for ease of formulation. Peazazz(R) can give your product a much-needed nutritional boost while staying dairy-free, soy-free and gluten-free.


About Burcon NutraScience Corporation
Burcon is a global technology leader in the development of plant-based proteins. The company has developed an extensive portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon's family of plant proteins includes Peazazz(R), a uniquely soluble and clean-tasting pea protein, Puratein(R), Supertein(R) and Nutratein(R) canola proteins with exceptional functionality and valuable nutritional profiles, and Nutratein-PS(TM) and Nutratein-TZ(TM), Burcon's new pea and canola protein blends that have exceptional functional characteristics, low allergenicity, and a nutritional value exceeding those of standard pea proteins in the market today. Burcon's CLARISOY(R) soy protein - under license to the Archer Daniels Midland Company - offers clarity and high-quality protein nutrition for low-pH beverage systems, and excellent solubility and exceptionally clean flavour at any pH. For more information about the company, visit www.burcon.ca.


The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward- looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated July 2, 2019 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.

CLARISOY is a trademark of Archer Daniels Midland Company.

Investor Contact:
Paul Lam
Manager, Business Development
Burcon NutraScience Corporation
Tel (604) 733-0896, Toll-free (888) 408-7960
plam@burcon.ca www.burcon.ca

Media Contact:
Steve Campbell, APR
President
Campbell & Company Public Relations
Tel (604) 888-5267
TECH@CCOM-PR.COM



26.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Anleihe im Fokus

PREOS Real Estate AG
"7,5%-Wandelanleihe - Jetzt bis 04.12.19 zeichnen!"

- Emissionsvolumen: bis zu 300 Mio. EUR
- Zeichnungsfrist: 19.11. bis 04.12.2019
- ISIN: DE 000A254NA6 / WKN: A254NA
- Börsenesegment: Börse Frankfurt, Open Market
- Stückelung: 1.000 EUR
- Zinssatz (Kupon): 7,5% p.a., jährliche Zahlung
- Laufzeit: 5 Jahre
- Endfälligkeit: 09.12.2024

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Media and Games Invest wächst dynamisch und profitabel

Innerhalb des Konzerns Media and Games Invest sind der wachstumsstarke Game-Publisher gamigo AG sowie Unternehmen aus dem dynamischen Bereich „Digital Media“ gebündelt. Der Wachstumskurs der Gesellschaft soll sowohl auf Basis eines anhaltenden anorganischen Wachstums sowie durch den Ausbau des bestehenden Geschäftes fortgesetzt werden. Im Rahmen unserer Initial-Coverage-Studie haben wir ein Kursziel von 1,90 € je Aktie ermittelt und vergeben das Rating KAUFEN..

News im Fokus

Vonovia SE: Vonovia currently controls 72.3% of the votes in Hembla (news with additional features)

21. November 2019, 19:59

Aktuelle Research-Studie

windeln.de SE

Original-Research: windeln.de SE (von Montega AG): n.a.

22. November 2019